Related Experiment Videos
High-dose cyclophosphamide for refractory autoimmune hemolytic anemia
Victor M Moyo1, Douglas Smith, Isadore Brodsky
1Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
Blood
|July 2, 2002
Summary
High-dose cyclophosphamide effectively treats severe autoimmune hemolytic anemia. This chemotherapy regimen induced durable remissions in most patients who had not responded to other treatments.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Autoimmune hemolytic anemia (AIHA) is a condition where the immune system attacks red blood cells.
- Refractory AIHA cases often require aggressive treatment options.
- High-dose cyclophosphamide is a potent immunosuppressive agent.
Purpose of the Study:
- To evaluate the safety and efficacy of high-dose cyclophosphamide in patients with severe refractory AIHA.
- To assess remission rates and durability after treatment.
Main Methods:
- Nine patients with severe refractory AIHA, who had failed a median of 3 prior treatments, were enrolled.
- Treatment involved high-dose cyclophosphamide (50 mg/kg/day for 4 days) without stem cell rescue.
- Patient outcomes, including hemoglobin levels and neutrophil recovery, were monitored.
Main Results:
- Six out of nine patients achieved complete remission, with no relapses after a median 15-month follow-up.
- Three additional patients achieved partial remission, maintaining adequate hemoglobin levels without transfusions.
- The treatment was generally well-tolerated, with neutrophil recovery occurring around day 16.
Conclusions:
- High-dose cyclophosphamide is a safe and effective treatment for severe refractory autoimmune hemolytic anemia.
- This regimen can induce durable remissions in patients with limited therapeutic options.
- Further research may explore its role in AIHA management.